Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

NCT03595059 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03595059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03595059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
July 13, 2018
Completion date
September 12, 2025
Enrollment
168 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors